source
- Ionis shares tumble over $1 billion as Tryngolza sales forecast cut in halfIonis Pharmaceuticals saw its market value drop by more than $1 billion after it lowered its sales outlook for Tryngolza, a triglyceride‑lowering therapy. The company now expects $50 million in sa…
- BIO unveils plan for US to remain biotech’s ‘global leader’A seven-part proposal from the prominent lobbyist lays out a series of initiatives to accelerate drug development in the U.S. and counter China’s fast rise.BioPharma Dive · 1h ago↗ source
- FDA approves Bayer’s Sunharbo, first Factor XIa inhibitor to lower stroke recurrence risk